ArticleJCEM case reports2025
Pituitary Xanthogranuloma Causing Sellar Mass in 2 Children With Hypopituitarism and Elevated Inflammatory Markers.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary xanthogranulomas represent a rare group of inflammatory pituitary masses. The prevalence of these lesions is not clearly defined. These lesions, also known as cholesterol granulomas, are diagnosed on histopathological findings including cholesterol clefts, hemosiderin deposits, foamy macrophages, and necrosis. They often present with pituitary hormone deficiencies and have a low recurrence rate following gross total resection. We describe 2 patients presenting with headaches, polyuria, polydipsia, and elevated erythrocyte sedimentation rate. One patient had a history of Rathke cleft cyst (RCC). Magnetic resonance imaging identified sellar masses, and they were subsequently diagnosed with varying degrees of pituitary hormone deficiencies preoperatively. They underwent transsphenoidal mass resection with pathology showing xanthogranuloma. Postoperatively they have panhypopituitarism including arginine vasopressin deficiency and no recurrence of the lesion. Inflammatory causes of pituitary lesions should remain on the differential, especially in patients with a history of RCC. More research is needed to identify the prevalence of xanthogranulomatous pituitary lesions and better understand the pathophysiology of their formation. The finding of elevated inflammatory markers, not usually seen in other pituitary masses or previously documented in the literature in cases of xanthogranulomatous pituitary lesions, could reflect a clinical clue when evaluating patients with pituitary lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.